BCM
SEEL

Bayesian Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History

Bayesian Capital Management’s Portfolio SEEL Stock Details SEEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-5
Closed -$52K – 586
2021
Q2 		$52K Buy
+5
New +$82.2K 0.01% 382

Other funds holding SEEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Bayesian Capital Management's SEEL Position: Q3 2021 in Review

Bayesian Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2021, closing a stake of 5 shares — an estimated $52K sold.

Bayesian Capital Management first reported a position in SEEL in Q2 2021 and held it in 1 quarter. The position peaked at $52K in Q2 2021. 95 funds tracked by Wall St. Rank hold SEEL as of Q3 2021.

  • Bayesian Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Bayesian Capital Management sold 5 Seelos Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $52K.
  • Bayesian Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • Bayesian Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $52K in Q2 2021.
  • 95 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2021.

Based on Bayesian Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.